Compare
Ernexa Therapeutics Inc. vs AEON Biopharma, Inc. vs GeoVax Labs, Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | Ernexa Therapeutics Inc. ERNA | AEON Biopharma, Inc. AEON | GeoVax Labs, Inc. GOVX | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $2.49M | $1.01M |
| Revenue growth (YoY) | n/a | n/a | -37.1% | +65.5% |
| Gross margin | n/a | n/a | n/a | 22.3% |
| Operating margin | n/a | n/a | -869.3% | -771.6% |
| Net margin | n/a | n/a | -862.3% | -732.5% |
| Net income | -$14.08M | -$39.22M | -$21.46M | -$7.37M |
| EPS (Diluted) | -$2.24 | -$3.95 | n/a | -$11.73 |
| Operating cash flow | -$7.02M | -$17.31M | -$21.47M | -$6.85M |
| Free cash flow | -$7.05M | -$17.31M | -$21.50M | -$6.99M |
| Cash & equivalents | n/a | $3.01M | $3.09M | $1.51M |
| Total assets | $5.83M | $5.56M | $6.34M | $5.37M |
| Total liabilities | $3.43M | $60.59M | $2.52M | $1.99M |
| Shareholders' equity | $2.40M | -$55.03M | $3.83M | $3.46M |
| Return on year-end equity | -586.6% | n/a | -561.2% | -212.7% |
| Shares outstanding | 7.85M | 12.11M | 1.73M | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | Ernexa Therapeutics Inc. | AEON Biopharma, Inc. | GeoVax Labs, Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $582.0K Ended 2024-12-31 | n/a | $2.49M Ended 2025-12-31 | $1.01M Ended 2025-12-31 |
| 1 year earlier | $68.0K Ended 2023-12-31 | n/a | $3.95M Ended 2024-12-31 | $607.6K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2022-12-31 | n/a | $0 Ended 2023-12-31 | $253.6K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $81.5K Ended 2022-12-31 | $223.2K Ended 2022-12-31 |
| 4 years earlier | $5.80M Ended 2020-12-31 | n/a | $385.5K Ended 2021-12-31 | n/a |